Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Revenue History
Annual and quarterly revenue from 2021 to present
CTNM Revenue Over Time (2021–2025)
CTNM Revenue Growth History
0 of 1 years with positive growth- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- -100.0%
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
CTNM Revenue Analysis (2021–2025)
Current Revenue & Growth
As of June 12, 2026, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
CTNM's historical revenue data shows various trends over time. Contineum Therapeutics, Inc. Class A Common Stock's highest annual revenue of $50.0 million was recorded in 2023.
Peer Comparison
Compared to Healthcare sector peers — including PRTA (-58.0% YoY), ARQT (+95.3% YoY), and KYMR (-12.6% YoY). Compare CTNM vs PRTA →
CTNM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 CTNMCurrent | $0 | - | - | - | |
 PRTA | $10M | -58.0% | +62.6% | -1905.8% | |
 ARQT | $376M | +95.3% | - | -3.3% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% |
CTNM Historical Revenue Data (2021–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-68,059,000 | - |
| 2024 | $0 | -100.0% | $-258,000 | - | $-50,894,000 | - |
| 2023 | $50.0M | - | $50.0M | 100.0% | $-16,077,000 | -32.2% |
| 2022 | $0 | - | $0 | - | $-22,720,000 | - |
| 2021 | $0 | - | $0 | - | $-28,647,000 | - |
What if you invested $1,000 in CTNM back in 2021?
Total return with dividends reinvested · 5+ years of data
Calculate ReturnsHow much would $100/month in CTNM be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs CTNM Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCTNM vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowCTNM — Frequently Asked Questions
Quick answers to the most common questions about buying CTNM stock.
Is CTNM's revenue growth accelerating or slowing?
CTNM TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is CTNM's revenue history from 2021 to 2026?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) revenue history spans 2021 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CTNM's long-term revenue growth rate (CAGR)?
Contineum Therapeutics, Inc. Class A Common Stock's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CTNM.
Why does CTNM's quarterly revenue fluctuate?
CTNM quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Contineum Therapeutics, Inc. Class A Common Stock's revenue data from 2021 to 2026 shows full historical quarterly detail on this page.
How is CTNM's revenue distributed by segment?
CTNM reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CTNM's revenue compare to industry peers?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.